跳至主要内容
临床试验/JPRN-UMIN000007668
JPRN-UMIN000007668已完成未知

Randomized control study to investigate the effect of rifampicin on prevention of recurrence in patients after radical treatment of primary hepatocellular carcinoma - Randomized control study to investigate the effect of rifampicin on prevention of recurrence in patients after radical treatment of primary hepatocellular carcinoma

Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University0 个研究点目标入组 40 人开始时间: 2012年4月9日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 80years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • (1) Not consent to observe the regulation about concomitant drug and concomitant therapy (2) Patients with complications that influence on serum alanine aminotransferase or aspartate aminotransferase, including polymyositis, acute myocardial infarction, and gallstone. (3) Patients under dialysis therapy (4) Patients with liver diseases due to chronic viral hepatitis (except for Hepatitis C virus), liver failure, alcohol abuse, drug-induced liver damage, autoimuune hepatitis, and primary biliary cirrhosis. (5) Patients with obstruction of bile duct. Patients with severe liver diseases, who meet one of following criteria; # Child-Pugh grade C # Hepatic encephalopathy # Total bilirubin >= 3mg/dL # Decompensated liver cirrhosis # AST >= 500IU/L # ALT >= 500IU/L (6) Patient with any other cancer (7) Patients of porphyria (8) Past history of hypersensitivity for Rifampicin (9) Preceding administration of other investigational agent within 24 weeks before enrollment of this study (10) Patients with pregnancy, lactation or possibility of pregnancy. Not consent to use contraceptive method during the study treatment. (11) Patients with active infectious diseases due to methicillin-resistant Staphylococcus aureus, atypical Mycobacteria, and Mycobacterium tuberculosis (12) Patients under chemotherapy of anti-cancer drug (Local or Systemic) or radiotherapy (13) Preceding enrollment of this study, and preceding administration of Rifampicin in this study (14) Any patients judged by the investigators to be unfit to participate in the study

研究者

发起方
Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University

相似试验